8-K: Mineralys Therapeutics Announces Positive Phase 2 Advance-HTN Trial Results for Lorundrostat in Uncontrolled Hypertension

Mineralys Therapeutics reports positive results from its Phase 2 Advance-HTN trial, demonstrating lorundrostat's efficacy in reducing blood pressure in patients with uncontrolled or resistant hypertension.

Summary

• Mineralys Therapeutics announced detailed results from the Phase 2 Advance-HTN trial of lorundrostat for uncontrolled and resistant hypertension.
• The trial evaluated lorundrostat as an add-on therapy to optimized background antihypertensive medications.
• The 50 mg dose of lorundrostat achieved a 7.9 mmHg placebo-adjusted reduction in 24-hour average systolic blood pressure (SBP) at Week 12 (p=0.001).
• The 50 to 100 mg dose of lorundrostat achieved a 6.5 mmHg placebo-adjusted reduction in 24-hour average SBP at Week 12 (p=0.006).
• At Week 4, the 50 mg dose showed an 11.5 mmHg absolute reduction and a 5.3 mmHg placebo-adjusted reduction in 24-hour average SBP (p<0.001).
• 41% of patients on lorundrostat 50 mg achieved a 24-hour average SBP < 125 mmHg at Week 4, compared to 18% on placebo (p<0.001).
• Lorundrostat demonstrated a favorable safety and tolerability profile with modest changes in potassium, sodium, and eGFR.
• The incidence of confirmed hyperkalemia (serum potassium >6.0 mmol/L) was 2.1% and 3.2% in the 50 mg and 50 to 100 mg arms, respectively.
• Serious adverse events (SAEs) occurred in 6%, 8%, and 2% of patients in the lorundrostat 50 mg, lorundrostat 50 to 100 mg, and placebo arms, respectively.
• Treatment-related SAEs occurred in 2%, 1%, and 0% of patients in the lorundrostat 50 mg, lorundrostat 50 to 100 mg, and placebo arms, respectively.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results with a favorable safety profile, suggesting a promising outlook for lorundrostat. The management's comments are optimistic, and the data supports the potential of the drug to address an unmet need in hypertension treatment.

Positives

• Lorundrostat demonstrated statistically significant reductions in blood pressure compared to placebo.
• The drug showed a favorable safety and tolerability profile.
• The study included a diverse patient population, including a significant representation of women and Black individuals.
• The observed changes in serum electrolytes were modest and reversible upon discontinuation of lorundrostat.
• There was a very low incidence of drug-related serious adverse events.

Negatives

• The incidence of hyperkalemia, although manageable, was observed in the lorundrostat treatment arms.
• SAEs occurred in 6% and 8% of patients in the lorundrostat 50 mg and 50 to 100 mg arms, respectively, compared to 2% in the placebo arm.

Risks

• The long-term safety and efficacy of lorundrostat need to be further evaluated.
• Regulatory approval is not guaranteed, and the FDA may require additional data.
• The commercial success of lorundrostat depends on market acceptance and competition from existing hypertension treatments.

Future Outlook

Mineralys plans to provide additional data from the pivotal Phase 3 Launch-HTN trial at an upcoming medical conference and in a peer-reviewed publication, and the ongoing Transform-HTN open-label extension trial will provide additional safety and efficacy data.

Management Comments

• Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, stated that the data demonstrates the robust and consistent blood pressure reductions of lorundrostat in two distinct patient populations.
• Luke Laffin, M.D., noted the double-digit drop in blood pressure readings observed with lorundrostat, given the complex characteristics of the patient population.
• David Rodman, MD, Chief Medical Officer of Mineralys Therapeutics, highlighted the manageable and reversible effects on serum electrolytes and the low rates of treatment discontinuation due to adverse events.

Industry Context

The results position lorundrostat as a potential best-in-class treatment for high-risk patients with uncontrolled or resistant hypertension, addressing a significant unmet need in hypertension care, especially in patients who are not adequately controlled with existing medications.

Comparison to Industry Standards

• The 7.9 mmHg placebo-adjusted reduction in systolic blood pressure at week 12 is clinically meaningful and compares favorably to other antihypertensive agents.
• The safety profile of lorundrostat appears competitive with existing treatments, particularly regarding the low incidence of serious drug-related adverse events.
• Companies like Novartis (Entresto), AstraZeneca (Farxiga), and Boehringer Ingelheim (Jardiance) have established successful cardiovascular drugs, and lorundrostat aims to address a specific segment of hypertension patients not adequately served by these existing therapies.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Patients with uncontrolled or resistant hypertension may have a new treatment option.
• Healthcare providers may have a new tool to manage hypertension more effectively.

Next Steps

• Mineralys plans to present additional data from the Phase 3 Launch-HTN trial.
• The company will continue the Transform-HTN open-label extension trial to gather additional safety and efficacy data.
• Mineralys will host a conference call to discuss the results.

Key Dates

Keywords

lorundrostat, hypertension, resistant hypertension, uncontrolled hypertension, Mineralys Therapeutics, Advance-HTN trial, aldosterone synthase inhibitor, blood pressure reduction, clinical trial, cardiorenal